Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20-05-2020
Ugis Rigba / Shutterstock.com
A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative (IMI) as favouring Big Pharma over small businesses, particularly when it comes to IP.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Innovative Medicines Initiative, IMI, NGO, PPP, EFPIA, Big Pharma, R&D, IP, licensing, European Commission, biopharmaceuticals
